Konakion Mm Ampoules

Phytomenadione, the active ingredient in Konakion Mm Ampoules, is a vitamin K presented as an injectable solution (ampoules) for intravenous use. It is employed to prevent and treat vitamin K deficiency, manage bleeding associated with anticoagulant therapy, and provide neonatal prophylaxis against hemorrhagic disease of the newborn. GNH USA supplies Konakion Mm Ampoules as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Konakion Mm Ampoules provides vitamin K1 for conditions where clotting factor synthesis is impaired. - Vitamin K deficiency: restores normal coagulation by enabling functional clotting factor production. - Anticoagulant‑related bleeding: reverses excess anticoagulation, such as warfarin overdose, to control hemorrhage. - Neonatal hemorrhagic disease prophylaxis: prevents bleeding in newborns at risk of vitamin K deficiency.

Adverse reactions may occur following intravenous administration of vitamin K1.

Common Side Effects: - Injection site pain: mild discomfort at the site of administration. - Erythema or swelling: localized redness or edema. - Flushing or warmth: transient sensation of heat. - Hypotension: temporary drop in blood pressure.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Hemolysis: destruction of red blood cells, reported rarely. - Thrombosis: formation of abnormal clots in blood vessels.

Use Konakion Mm Ampoules with clinical monitoring and appropriate precautions. - Assess coagulation status: evaluate INR or PT before administration. - Monitor for hypersensitivity: observe for signs of allergic reaction during and after infusion. - Caution with warfarin therapy: adjust anticoagulant dosing as vitamin K may counteract its effect. - Known vitamin K allergy: avoid use in patients with documented hypersensitivity. - Neonatal use: follow pediatric dosing guidelines and monitor bilirubin levels. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vitamin K1 can interact with several medications affecting coagulation.

Major Interactions (Avoid): - Concurrent high‑dose warfarin: may blunt the anticoagulant effect, leading to therapeutic failure. - Prothrombin complex concentrates: combined use can increase risk of thrombosis.

Moderate Interactions (Monitor Closely): - Antibiotics (e.g., broad‑spectrum cephalosporins): may alter vitamin K metabolism, requiring monitoring of coagulation parameters. - Cholestyramine or other bile‑acid sequestrants: can reduce vitamin K availability if administered shortly after injection. - Antiplatelet agents (e.g., aspirin): monitor for enhanced clotting or bleeding risk.